I put my 11-year-old daughter on weight-loss jabs. Six weeks after her first dose, I had to rush her to hospital. This is why I have no regrets: ASHLEY HAMILTON
'I've just thrown up and it hurts Mum,' she said. 'I feel like I'm going to die.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
24 minutes ago
- The Independent
Urgent warning over virus dangerous to newborns as cases surge abroad
Health experts say the UK should brace for a surge in a potentially serious virus following a record number of cases in Australia. NHS officials said that the Australian winter is often a good predictor of how viruses will spread in England. In Australia, respiratory syncytial virus (RSV) cases have surged in recent months, and officials have said that cases have been steadily increasing in England since the start of 2025. NHS England has urged pregnant women to get the vaccine, which protects against RSV, in order to protect their newborn babies. The virus is a leading cause of death among babies and the main cause of hospital admissions for children. Kate Brintworth, chief midwifery officer for NHS England, said that while for most adults, RSV 'only causes mild, cold-like symptoms, for older adults and young children, it can lead to serious breathing problems that can end up in hospitalisation'. 'Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating.' Pregnant women can get the jab from 28 weeks of pregnancy onwards through their maternity services or GP surgery. Older adults aged 75-79 are also eligible for the jab, and NHS England will start inviting people to come forward in the next few weeks. Symptoms of an RSV infection NHS RSV is a common cause of coughs and colds, but some people have a high risk of getting seriously ill from the virus, including babies and adults over the age of 75. In babies, RSV is a common cause of a type of chest infection called bronchiolitis. Last week, the UK Health Security Agency published data showing the efficacy of the vaccine. It said that the jab for pregnant women can prevent 72 per cent of hospital admissions for their babies. And the vaccine is 82 per cent effective at preventing hospital admissions for RSV among older adults, UKHSA said.
The Sun
24 minutes ago
- The Sun
Thousands of Brits urged to ‘get vaccinated now' to protect against killer bug often mistaken for a cold
THOUSANDS of Brits are being urged to take up a jab that protects against a sometimes deadly "cold-like" virus. The vaccine for respiratory syncytial virus (RSV) is offered to pregnant mum's to protect unborn babies from the disease expected to surge in the coming months. 1 RSV is a common infection, which in the majority of people, just causes mild, flu -like symptoms, similar to the common cold. It can, on occasion, lead to chest infections like bronchiolitis and pneumonia, especially in newborns and the elderly. Each year it kills around 8,000 people in the UK and hospitalises tens of thousands more. Experts think the UK should brace for a surge this autumn, when the disease typically rears its head, following a record number of cases in Australia. NHS officials said that the Australian winter is often a good predictor of how viruses will spread in England. And following a surge in cases number of RSV cases in Australia, officials have said that cases have been steadily increasing in England since the start of 2025. NHS England has urged pregnant women to get the RSV vaccine to protect their babies, as the virus is a leading cause of infant deaths and the top reason for hospital admissions in young children. Kate Brintworth, chief midwifery officer for NHS England, said: "While for most adults RSV only causes mild, cold-like symptoms, for older adults and young children it can lead to serious breathing problems that can end up in hospitalisation. "Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating." Pregnant women can get the jab from 28 weeks of pregnancy onwards through their maternity services or GP surgery. RSV vaccine Older adults aged 75-79 are also eligible for the jab and NHS England will start inviting people to come forward in the next few weeks. Last week, the UK Health Security Agency (UKHSA) published data showing the efficacy of the vaccine, which was first rolled out in summer 2024. It said that the jab for pregnant women can prevent 72 per cent of hospital admissions for their babies. The antibodies the mums produce in response to the jab are passed to their babies in the womb, protecting them for the first six months after being born. And the vaccine is 82 per cent effective at preventing hospital admissions for RSV among older adults, UKHSA said. Higher risk babies can receive the nirsevimab vaccine from September – with the single jab replacing five monthly injections previously given to infants classed as being at high risk. It will protect them against RSV which is even more serious in high-risk infants. Around 7,000 babies will be eligible and get about 80 per cent protection for six months from a single injection. The previous weekly treatment was only 55 per cent effective.
BBC News
24 minutes ago
- BBC News
Obesity jabs: Help needed to keep weight off after stopping them
People coming off obesity jabs like Wegovy and Mounjaro should have check-ups for at least a year to make sure they don't pile weight back on, new advice for the NHS not uncommon for people to regain most of what they shed once they stop treatment, experience shows. The guidance, from health assessment body NICE, warns weight management is a long-term journey, not a short-term may need extra support and a plan for how to stay at their new weight, such as eating healthily and hitting the gym or going for walks, it says. In England alone, obesity affects around one in four estimated 1.5 million people are on weight loss jabs in the UK, but the vast majority are paying for them privately so will not be eligible for NHS support as they come off the (semaglutide) is already available on the NHS on prescription, but only to those most in need (with health problems due to their weight and a high BMI) for a period of two 240,000 people are expected to be offered Mounjaro (tirzepatide) over the next three years. There's currently no specified time limit for being prescribed the drugs help reduce appetite and can lead to life-changing weight loss. They are prescribed alongside programmes that support healthy weight loss through changes to diet and physical a Wegovy drug trial, patients regained around two-thirds of their original weight once they came off the injections. It's a similar story for those on advice from NICE, the National Institute for Health and Care Excellence, encourages patients to build long-term behavioural habits, use self-monitoring tools, and draw on wider support "from online communities to family-led interventions and local activities."Prof Jonathan Benger from NICE said: "Successful weight management doesn't end when medication stops or when someone completes a behavioural programme."We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made."Prof Kamila Hawthorn from the Royal College of GPs said: "There is no one-size fits all approach to tackling obesity - what works for one patient will likely not work for another."We also need to see a greater focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later."Obesity can cause people difficulties in their daily lives, and put them at more risk of serious health problems, such as heart disease, type 2 diabetes, and some types of cancer.
